|
|
 | | | |
- close
- close
- close
- close
Vanda Pharmaceuticals (VNDA) |
StreetInsider.com
May 17
Comment
Real Goods Solar (Nasdaq: RSOL) 91.7% HIGHER; possibly moving higher on a bullish blog post today. Only 1.3 percent of float is being held short currently.
Aruba Networks (Nasdaq: ARUN) 27.2% LOWER; getting crushed after issuing Q4 guidance with...
Benzinga
May 17
Comment
Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares advanced 24.50% to $1.88 at 9:46 am. Seanergy Maritime's trailing twelve-month revenue is $55.62 million.
Real Goods Solar, Inc. (NASDAQ: RSOL) surged 22.06% to $2.14. Real Goods Solar has...
Benzinga
May 13
Comment
Virtus Investment Partners, Inc. (NASDAQ: VRTS) shares moved up 0.69% to create a new 52-week high of $222.85. Virtus Investment Partners has trailing twelve-month revenue of $303.86 million.
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) shares...
Benzinga
Apr 17
Comment
Vanda Pharmaceuticals (NASDAQ: VNDA), announced today that it has named Paolo Baroldi, M.D., Ph.D. as its Senior Vice President and Chief Medical Officer.
Dr. Baroldi has over 30 years of clinical development experience in many therapeutic...
StreetInsider.com
Mar 25
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vanda+Pharma+%28VNDA%29+Completes+Tasimelteon+pre-NDA+with+FDA+Unit/8207877.html for the full story.
Benzinga
Mar 14
Comment
Vanda Pharmaceuticals (NASDAQ: VNDA) announced today that it has withdrawn its Marketing Authorization Application (MAA) submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Fanaptum™ (oral...
Benzinga
Mar 6
Comment
In a report published Wednesday, Piper Jaffray initiated coverage on Vanda Pharmaceuticals (NASDAQ: VNDA) with an Overweight rating and $8.00 price target.
Piper Jaffray noted, “In our view, Vanda presents an overlooked opportunity in an...
StreetInsider.com
Feb 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vanda+Pharmaceuticals+%28VNDA%29+Misses+Q4+EPS+by+1c/8082716.html for the full story.
FierceBiotech
Jan 31
Comment
Shares of Vanda Pharmaceuticals ($VNDA) took a hit this morning after the biotech said that tasimelteon had failed a Phase II/III study for depression. The drug performed just about as well as a placebo, a common occurrence in the depression R&D...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
